Pharmacology of the short QT syndrome N588K‐hERG K⁺ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs

Abstract

The degree of drug inhibition of hERG channels may vary based on the level of channel inactivation. Drugs previously identified as useful for treating SQT1 have the least dependence on hERG inactivation. In addition, our findings indicate that amiodarone may warrant further investigation as a potential treatment for SQT1.